259188-38-0

Usage

InChI:InChI=1/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1

Upstream product

• 35661-60-0 Fmoc-Leu-OH 
• 89226-12-0 (S)-2-amino-N,3,3-trimethylbutanamide 
• 860803-16-3 N-[2-chloro-4-(1,5,5-trimethylhydantyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide 
• 860803-15-2 [(S)-1-((S)-2,2-Dimethyl-1-methylcarbamoyl-propylcarbamoyl)-3-methyl-butyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 860803-14-1 (R)-2-chloro-4-(1,5,5-trimethylhydantyl)butanoic acid pentachlorophenyl ester 
• 178933-95-4 L-leucyl-L-tert-leucine methyl amide 

Relevant academic research and scientific papers

Performing the synthesis of a complex molecule on sequentially linked columns: Toward the development of a "synthesis machine"

(Chemical Equation Presented) We describe the diastereoselective synthesis of a pharmaceutically active drug candidate via a column-based system. This methodology is complementary to classical solid-phase synthesis; individual columns are packed with resi

PEPTIDYL COMPOUNDS

Dipeptide compounds have therapeutic utility, inter alia, as metalloproteinase and TNF inhibitors.